Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK2206
MK2206 every other day · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| QOD Schedule | EXPERIMENTAL | QOD Schedule, MK2206 every other day |
| QW Schedule | EXPERIMENTAL | QW Schedule, MK2206 once weekly |
| Name | Type | Description |
|---|---|---|
| MK2206 every other day | DRUG | Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles. |
| MK2206 once weekly | DRUG | Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles. |
Inclusion Criteria: * Patient must have confirmed locally advanced or metastatic solid tumors that have failed to respond to standard therapy, have gotten worse or have come back after existing therapy * Has adequate organ function * Is ECOG Performance Scale 0-1 * Has a negative urine pregnancy te...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MK2206 every other day refers to an intermittent dosing schedule of MK2206, an investigational small molecule developed by Merck & Company, Inc. (MRK). It was studied in a Phase 1 trial in patients with locally advanced or metastatic solid tumors. The every-other-day schedule was used to evaluate tolerability of the drug when given on an intermittent basis.
MK2206 every other day was studied for the treatment of locally advanced or metastatic solid tumors. The Phase 1 trial NCT01071018 evaluated this dosing schedule in adult patients with solid tumors. It is an investigational therapy and is not approved for any indication.
MK2206 targets AKT1, AKT2, and AKT3, which are members of the AKT kinase family. It acts as an inhibitor of these targets. By inhibiting AKT signaling, the drug aims to interfere with pathways involved in tumor cell survival and proliferation in solid tumors.
MK2206 is developed by Merck & Company, Inc., which trades under the ticker MRK. The every-other-day schedule is a dosing regimen studied by Merck in its clinical program for solid tumors.
MK2206 every other day is in Phase 1 clinical development. The only trial listed, NCT01071018, is a completed Phase 1 study. The drug is investigational and has not been approved by the FDA for any indication.
MK2206 every other day has been evaluated in one clinical trial: NCT01071018, titled "A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)." This Phase 1 trial enrolled 24 patients and is completed. No active trials are currently listed for this dosing schedule.